IRulya Therapeutics Inc. (IRLA) stock
IRLANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 5/30
$40.59+2.14 (+5.57%)
Close on Nov 18, 2026Market cap $41.28MP/E –Yield –
IRulya Therapeutics cash
Cash and short-term investments held at the end of each period.
IRulya Therapeutics's cash was $116.00M at Jun 30, 2026. For fiscal 2025 it was $17.80M, down 56.4% from the year before. The highest annual figure on record is $133.80M in fiscal 2020.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.80M | -56.4% |
| FY2024 | Dec 31, 2024 | $40.80M | -45.7% |
| FY2023 | Dec 31, 2023 | $75.10M | -16.7% |
| FY2022 | Dec 31, 2022 | $90.20M | -15.5% |
| FY2021 | Dec 31, 2021 | $106.80M | -20.2% |
| FY2020 | Dec 31, 2020 | $133.80M | +33.9% |
| FY2019 | Dec 31, 2019 | $99.90M | +39.3% |
| FY2018 | Dec 31, 2018 | $71.72M | +870.1% |
| FY2017 | Dec 31, 2017 | $7.39M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $116.00M | +234.3% |
| Q1 FY2026 | Mar 31, 2026 | $18.20M | -42.4% |
| Q4 FY2025 | Dec 31, 2025 | $17.80M | -56.4% |
| Q3 FY2025 | Sep 30, 2025 | $26.30M | -45.0% |
| Q2 FY2025 | Jun 30, 2025 | $34.70M | -41.6% |
| Q1 FY2025 | Mar 31, 2025 | $31.60M | -53.4% |
| Q4 FY2024 | Dec 31, 2024 | $40.80M | -45.7% |
| Q3 FY2024 | Sep 30, 2024 | $47.80M | -42.5% |
| Q2 FY2024 | Jun 30, 2024 | $59.40M | -32.2% |
| Q1 FY2024 | Mar 31, 2024 | $67.80M | -24.8% |
| Q4 FY2023 | Dec 31, 2023 | $75.10M | -16.7% |
| Q3 FY2023 | Sep 30, 2023 | $83.20M | -11.8% |
| Q2 FY2023 | Jun 30, 2023 | $87.60M | -7.5% |
| Q1 FY2023 | Mar 31, 2023 | $90.20M | -1.4% |
| Q4 FY2022 | Dec 31, 2022 | $90.20M | -15.5% |
| Q3 FY2022 | Sep 30, 2022 | $94.30M | -17.6% |
| Q2 FY2022 | Jun 30, 2022 | $94.70M | -27.2% |
| Q1 FY2022 | Mar 31, 2022 | $91.50M | -37.8% |
| Q4 FY2021 | Dec 31, 2021 | $106.80M | -20.2% |
| Q3 FY2021 | Sep 30, 2021 | $114.40M | -17.0% |
| Q2 FY2021 | Jun 30, 2021 | $130.00M | -10.0% |
| Q1 FY2021 | Mar 31, 2021 | $147.00M | -9.5% |
| Q4 FY2020 | Dec 31, 2020 | $133.80M | +33.9% |
| Q3 FY2020 | Sep 30, 2020 | $137.80M | +14.4% |
| Q2 FY2020 | Jun 30, 2020 | $144.50M | +12.6% |
| Q1 FY2020 | Mar 31, 2020 | $162.40M | +175.3% |
| Q4 FY2019 | Dec 31, 2019 | $99.90M | +39.3% |
| Q3 FY2019 | Sep 30, 2019 | $120.50M | +341.5% |
| Q2 FY2019 | Jun 30, 2019 | $128.30M | +65.6% |
| Q1 FY2019 | Mar 31, 2019 | $59.00M | +1239.7% |
| Q4 FY2018 | Dec 31, 2018 | $71.72M | +870.1% |
| Q3 FY2018 | Sep 30, 2018 | $27.29M | – |
| Q2 FY2018 | Jun 30, 2018 | $77.47M | – |
| Q1 FY2018 | Mar 31, 2018 | $4.40M | – |
| Q4 FY2017 | Dec 31, 2017 | $7.39M | – |
See a number that looks wrong?